Abstract
Background
The feasibility and significance of imaging pulmonary artery (PA) remodeling with 68 Ga-fibroblast activating protein inhibitor (FAPI) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) have not yet been addressed.
Methods
68 Ga-FAPI-04 uptake in the PA and ascending artery was evaluated in 13 patients with CTEPH and 13 matched non-CTEPH controls. The correlations of PA 68 Ga-FAPI-04 uptake and remodeling parameters derived from right heart catheterization (RHC) were analyzed.
Results
Of the 13 patients with CTEPH, nine (69%) showed visually enhanced 68 Ga-FAPI-04 uptake, whereas none of the control subjects had increased 68 Ga-FAPI-04 uptake in the PA. The prevalence of enhanced uptake in the main, lobar, and segmental PAs was 45% (17/38), 33% (16/48), and 28% (44/159), respectively. 68 Ga-FAPI-04 activity in the PA was positively correlated with pulmonary arterial diastolic pressure (r = 0.571, P = 0.041).
Conclusion
68 Ga-FAPI-04 has the potential for imaging fibroblast activation in the PA wall, and 68 Ga-FAPI-04 activity in PA is positively correlated with pulmonary arterial diastolic pressure.
Graphical abstract
This is a preview of subscription content, log in via an institution to check access.
Change history
19 September 2022
A Correction to this paper has been published: https://doi.org/10.1007/s12350-022-03104-3
References
Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res 2017;367:643‐9.
Chemla D, Lau EM, Papelier Y, Attal P, Hervé P. Pulmonary vascular resistance and compliance relationship in pulmonary hypertension. Eur Respir J 2015;46:1178‐89.
Bochenek ML, Rosinus NS, Lankeit M, Hobohm L, Bremmer F, Schütz E. From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2017;117:769‐83.
Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med 2019;60:1743‐9.
Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: Comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging 2022. https://doi.org/10.1007/s00259-021-05674-9.
Chen BX, Xing HQ, Gong JN, Guo XJ, Xi XY, Yang YH, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension. Eur J Nucl Med Mol Imaging 2022;49:1211‐22.
Wu M, Ning J, Li J, Lai Z, Shi X, Xing H, et al. Feasibility of in vivo imaging of fibroblast activation protein in human arterial walls. J Nucl Med 2021. https://doi.org/10.2967/jnumed.121.262863.
Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021;57:2002828.
Gao W, Gong JN, Guo XJ, Wu JY, Xi XY, Ma ZH, et al. Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu’s arteritis. Eur Heart J Cardiovasc Imaging 2021;22:541‐50.
Yamaki S, Ando M, Fukumoto Y, Higuchi Y, Kaneko K, Maeda K, et al. Histopathological examination by lung biopsy for the evaluation of operability and postoperative prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 2014;78:476‐82.
Miao R, Dong X, Gong J, Li Y, Guo X, Wang J, et al. Examining the development of chronic thromboembolic pulmonary hypertension at the single-cell level. Hypertension 2022;79:562‐74.
Dorfmüller P, Günther S, Ghigna MR, Thomas de Montpréville V, Boulate D, Paul JF, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: A role for pulmonary veins and systemic vasculature. Eur Respir J 2014;44:1275‐88.
Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013;41:217‐23.
Gerges C, Gerges M, Lang MB, Zhang Y, Jakowitsch J, Probst P, et al. Diastolic pulmonary vascular pressure gradient: A predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest 2013;143:758‐66.
Disclosure
This work was supported by the Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZYLX202105), the National Key Research and Development Program of China (2021YFF0501400 and 2021YFF0501401), and the National Natural Science Foundation of China (81871380 and 82071967).
Conflict of interest
No potential conflicts of interest relevant to this article exist.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: After publication, the author discovered and corrected mistakes in the text. The following updates to the text have been made: In the Abstract, under the Methods section, a correction in sentences 1 and 2 has been made whereby 68 Ga-FAPI has been changed to 68 Ga-FAPI-04. In the MATERIALS AND METHODS, paragraph 1, the two citations to Ref. [8] have been corrected to Ref. [6]. In the MATERIALS AND METHODS, paragraph 3, sentence 2, the acronym Pas has been corrected to PAs. In the Keywords, 68 Ga-FAPI has been corrected to 68 Ga-FAPI-04.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Gong, JN., Chen, BX., Xing, HQ. et al. Pulmonary artery imaging with 68 Ga-FAPI-04 in patients with chronic thromboembolic pulmonary hypertension. J. Nucl. Cardiol. 30, 1166–1172 (2023). https://doi.org/10.1007/s12350-022-03069-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-022-03069-3